Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.53

-1.6324 (-9.51%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

11:02
11/30/16
11/30
11:02
11/30/16
11:02

Takeda could be 'lured back' if Valeant increases Salix disclosures, FT says

After the Wall Street Journal reported that Valeant (VRX) and Takeda Pharmaceutical (TKPYY)have come to an impasse over the potential price of Salix in a sale, Financial Times reports that a person briefed about the deal said that Takeda "could be lured back to the table" if Valeant discloses more information about Salix's financials and business. Valeant shares are off their earlier lows, but remain down about 8% near 11 am ET. Reference Link

VRX

Valeant

$15.53

-1.6324 (-9.51%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

VRX Valeant
$15.53

-1.6324 (-9.51%)

11/18/16
DBAB
11/18/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche still likes near-term setup for Valeant shares
Deutsche Bank analyst Gregg Gilbert said yesterday that he still likes the near-term setup for shares of Valeant Pharmaceuticals after federal prosecutors announced criminal charges against former executive Gary Tanner and the former CEO of Philidor. It is "good to see" that Valeant and other senior executives were not charged, Gilbert told investors in a research note. The charges could be an important step forward as the company and new management team distance themselves from the past, Gilbert wrote. The analyst points out that the bar for 2016 has already been lowered and that new CFO Paul Herendeen thinks of guidance as a commitment. Gilbert keeps a Hold rating on Valeant with a $24 price target. The stock closed yesterday up 12c to $17.98.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
TKPYY Takeda Pharmaceutical Co. Ltd.
$20.97

-0.035 (-0.17%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

10:17
06/22/17
06/22
10:17
06/22/17
10:17
General news
Forcing Pelosi out would be 'very bad' for Republicans, Trump says »

President Donald Trump…

$NSD

NASDAQ Market Internals

10:17
06/22/17
06/22
10:17
06/22/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
06/22/17
06/22
10:16
06/22/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
06/22/17
06/22
10:15
06/22/17
10:15
General news
U.S. leading index rose 0.3% to 127.0 in May, an all time high »

U.S. leading index rose…

10:15
06/22/17
06/22
10:15
06/22/17
10:15
General news
Breaking General news story  »

Week of 6/16 EIA Natural…

SINA

SINA

$91.93

3.5 (3.96%)

, WB

Weibo

$76.96

2.88 (3.89%)

10:14
06/22/17
06/22
10:14
06/22/17
10:14
Hot Stocks
Chinese internet stocks fall following report of streaming ban »

Shares of Chinese…

SINA

SINA

$91.93

3.5 (3.96%)

WB

Weibo

$76.96

2.88 (3.89%)

FENG

Phoenix New Media

$2.69

-0.06 (-2.18%)

YY

YY

$58.98

0.89 (1.53%)

MOMO

Momo

$38.70

0.81 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ANF

Abercrombie & Fitch

$12.19

0.14 (1.16%)

10:10
06/22/17
06/22
10:10
06/22/17
10:10
Upgrade
Abercrombie & Fitch rating change  »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.43

0.59 (5.44%)

10:10
06/22/17
06/22
10:10
06/22/17
10:10
Options
5K Horizon Pharm Jan 15 calls opened for 89c when bid-ask was 45 to 90c »

5K Horizon Pharm Jan 15…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

10:08
06/22/17
06/22
10:08
06/22/17
10:08
Syndicate
Altice USA indicated to open at $31.50, IPO priced at $30 »

Altice USA (ATUS) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CVM

CEL-SCI

$1.80

0.11 (6.51%)

10:08
06/22/17
06/22
10:08
06/22/17
10:08
Hot Stocks
Breaking Hot Stocks news story on CEL-SCI »

Cel Sci trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$17.93

0.15 (0.84%)

10:07
06/22/17
06/22
10:07
06/22/17
10:07
Technical Analysis
Technical View: Twitter bounces higher for second session »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

SGBX

SG Blocks

10:06
06/22/17
06/22
10:06
06/22/17
10:06
Syndicate
Breaking Syndicate news story on SG Blocks »

SG Blocks opens at $4.75,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

IGLD

Internet Gold

10:06
06/22/17
06/22
10:06
06/22/17
10:06
Hot Stocks
Breaking Hot Stocks news story on Internet Gold »

Internet Gold trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$121.52

-5.59 (-4.40%)

10:04
06/22/17
06/22
10:04
06/22/17
10:04
Technical Analysis
Technical View: Accenture trades near lows of the day »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

GM

General Motors

$34.06

-0.07 (-0.21%)

10:04
06/22/17
06/22
10:04
06/22/17
10:04
Hot Stocks
GM reports 'successful' conclusion of three-year consent order with NHTSA »

General Motors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

10:01
06/22/17
06/22
10:01
06/22/17
10:01
General news
Leading Indicators data reported »

May Leading Indicators up…

IGLD

Internet Gold

10:01
06/22/17
06/22
10:01
06/22/17
10:01
Hot Stocks
Breaking Hot Stocks news story on Internet Gold »

Internet Gold trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$17.85

0.0699 (0.39%)

10:01
06/22/17
06/22
10:01
06/22/17
10:01
Hot Stocks
Twitter, Sela Sport announce live streaming partnership »

Twitter and Sela Sport…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

QQQ

PowerShares QQQ Trust

$140.74

1.38 (0.99%)

10:00
06/22/17
06/22
10:00
06/22/17
10:00
Options
Bullish three-way spread in PowerShares QQQ »

Bullish three-way spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRTO

Proteon Therapeutics

10:00
06/22/17
06/22
10:00
06/22/17
10:00
Hot Stocks
Breaking Hot Stocks news story on Proteon Therapeutics »

Proteon Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$1.81

-0.005 (-0.28%)

09:58
06/22/17
06/22
09:58
06/22/17
09:58
Hot Stocks
22nd Century receives guidance from FDA on Phase 3 clinical trials »

22nd Century announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFIE

Profire Energy

$1.31

-0.01 (-0.76%)

09:57
06/22/17
06/22
09:57
06/22/17
09:57
Conference/Events
Profire Energy management to meet with Maxim »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

WB

Weibo

$76.96

2.88 (3.89%)

, MOMO

Momo

$38.70

0.81 (2.14%)

09:55
06/22/17
06/22
09:55
06/22/17
09:55
Recommendations
Weibo, Momo analyst commentary  »

Jefferies sees no…

WB

Weibo

$76.96

2.88 (3.89%)

MOMO

Momo

$38.70

0.81 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.76

4.43 (9.56%)

, SPLS

Staples

$8.66

-0.09 (-1.03%)

09:55
06/22/17
06/22
09:55
06/22/17
09:55
Options
Early notable gainers among liquid option names on June 22nd »

Notable gainers among…

ORCL

Oracle

$50.76

4.43 (9.56%)

SPLS

Staples

$8.66

-0.09 (-1.03%)

KMX

CarMax

$62.14

2.4001 (4.02%)

RL

Ralph Lauren

$72.50

1.59 (2.24%)

UA

Under Armour

$18.93

0.18 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

  • 30

    Jun

CBRL

Cracker Barrel

$162.44

-0.9 (-0.55%)

09:51
06/22/17
06/22
09:51
06/22/17
09:51
Conference/Events
Cracker Barrel management to meet with Maxim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.